Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design.
siRNA therapeutics are currently regarded as promising candidates to make a leap forward in the search for treatments of various hard to cure diseases. In order to exploit the full potential of siRNA based therapeutics, development of delivery systems that can efficiently guide the siRNA molecules to their target without major side effects will be the key to success. Lipid based delivery systems, originating from earlier research in the fields of gene delivery, are the most studied candidates for siRNA delivery. Here we discuss the requirements that need to be met by these siRNA delivery systems to ensure adequate stability after systemic application and subsequent deposition in the target tissue. The encountered hurdles in the blood stream and the solutions proposed in literature are discussed.
Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmacy, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium.
Kevin
K
Buyens
Stefaan C
SC
De Smedt
Kevin
K
Braeckmans
Joseph
J
Demeester
Liesbeth
L
Peeters
Leo A
LA
van Grunsven
Xavier
X
de Mollerat du Jeu
Rupa
R
Sawant
Vladimir
V
Torchilin
Katarina
K
Farkasova
Manfred
M
Ogris
Niek N
NN
Sanders
D000818:Animals; D004337:Drug Carriers / Q000008:administration & dosage* / Q000737:chemistry; D004355:Drug Stability; D006801:Humans; D008081:Liposomes; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000737:chemistry
D004337:Drug Carriers; D008081:Liposomes; D034741:RNA, Small Interfering